Entecavir is new drug for chronic hepatitis B treatment
Authors:
J. Stránský
Authors‘ workplace:
I. interní klinika FNKV a 3. LF UK Praha
přednosta prof. MUDr. Jiří Horák, CSc.
10
Published in:
Prakt. Lék. 2006; 86(7): 391-392
Category:
Of different specialties
Overview
The antiviral treatment of chronic hepatitis B by interferons was significantly extended in last decade by synthetic nucleosides and nucleotides which are given perorally. Lamivudin (100 mg/day) was the first, adefovir dipivoxil (10 mg/day) was the second drug, and nowadays extensive clinical trials are continuing with entecavir (0.5 mg/day) which is an analogue of guanosine with high and selective antiviral activity against hepatitis B virus. It is given to HBeAg positive and negative patients with chronic hepatitis B and serological markers of viral replication. In comparison of entecavir to lamivudine treatment there was significantly higher histological, virological and biochemical improvement in entecavir. Safety and tolerance profil was similar in both drugs and no antiviral resistence to hepatitis B virus was meanwhile observed during 12 moths entecavir treatment.
Key words:
chronic hepatitis B, antiviral treatment, entecavir.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2006 Issue 7
Most read in this issue
- The diagnostic process in primary health care – the most frequent sources of errors and possibilities for their elimination
- Post-exercise acute rhabdomyolysis – benign sign or symptom of serious muscular disease?
- Entecavir is new drug for chronic hepatitis B treatment
- Recommended diagnostic steps for general practitioners attending patients with difficulties that could indicate multiple myeloma